Updated:
GT Medical Technologies
GT Medical Technologies commercializes GammaTile, a FDA-cleared implant that combines a collagen tile with radiation seeds to treat operable brain tumors.
GT Medical Technologies
GT Medical Technologies commercializes GammaTile, a FDA-cleared implant that combines a collagen tile with radiation seeds to treat operable brain tumors. Placed during tumor resection surgery, GammaTile begins delivering radiation immediately, eliminating the typical two-to-eight-week wait that follows conventional external-beam radiation. The tile structure positions radiation sources against residual tumor cells while the collagen matrix provides physical spacing that reduces dose to healthy brain tissue. GammaTile is indicated for newly diagnosed and recurrent glioblastoma, brain metastases, and recurrent meningiomas. Approximately 90 percent of the radiation dose is delivered within the first 30 days, after which the collagen tile fully dissolves in the body. The device addresses a structural gap in neuro-oncology where post-surgical waiting periods allow microscopic disease to regrow before radiation begins. By initiating treatment at closure, GammaTile does in weeks what external-beam protocols accomplish over a longer, fragmented schedule — reducing tumor-regrowth risk, protecting healthy tissue, and minimizing side effects including hair loss. The platform spans three major intracranial tumor categories and has accumulated clinical data across nine published references cited by the firm, with evidence of improved local control across glioblastoma and metastasis patient cohorts. GammaTile operates a center-locator tool pointing patients to treatment centers across the United States, indicating active commercial adoption among neurosurgery and radiation-oncology practices. The firm maintains an educational resource library and patient-story archive, signaling a direct-to-patient go-to-market layer uncommon in medical-device rollouts. No team page or named executives are publicly listed on the firm’s website, consistent with a lean commercial-stage organization that has not yet disclosed a management roster or organizational structure. GT Medical Technologies occupies a regulatory moat that a generic competitor cannot easily replicate — the device is the first and currently only tile-based radiation therapy for operable brain tumors, cleared via the FDA’s premarket pathway. That clearance, combined with a bioresorbable delivery mechanism requiring no second procedure for removal, creates a high barrier to fast-follow entrants. The firm’s public posture centers entirely on the product and its clinical evidence, placing it in a narrow class of single-asset medical-device companies where the asset itself functions as the sole visible corporate identity.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Tempe
Corporate office
Tempe, AZ, United States
Sector focus
Frequently asked questions
What does GT Medical Technologies actually make?
The firm makes GammaTile, a bioresorbable collagen tile embedded with radiation seeds that neurosurgeons place in the tumor cavity at the time of brain-tumor removal surgery. It is the first and only tile-based radiation therapy cleared by the FDA. The tile begins irradiating residual tumor cells immediately and dissolves over several weeks, eliminating the need for removal and avoiding the standard multi-week delay between surgery and external-beam radiation.
Which brain tumors does GammaTile address?
GammaTile is FDA-cleared for three operable brain-tumor categories: newly diagnosed glioblastoma, recurrent glioblastoma, brain metastases (both newly diagnosed and recurrent), and recurrent meningiomas. Collectively these represent the highest-volume intracranial tumors requiring post-resection radiation.
How does GammaTile differ from standard radiation therapy?
Standard external-beam radiation typically begins two to eight weeks after surgery because the surgical site must heal before conventional radiation can be tolerated. GammaTile is placed directly in the resection cavity during surgery and begins delivering radiation from day one — roughly 90 percent of the total dose is delivered within the first 30 days. The collagen tile physically separates the radiation sources from healthy brain tissue, reducing collateral dose. There is no daily hospital visit and no fractionated schedule.
Is GT Medical Technologies a venture-backed company or a subsidiary of a larger medical-device firm?
The firm’s website does not disclose a parent company, corporate structure, or named investors. No public funding rounds, executive team, or board of directors are listed in the firm’s online presence. The available information does not confirm venture backing or affiliation with a larger strategic — only that the entity operates commercially out of Tempe, Arizona under the GammaTile brand.
Where can a patient receive GammaTile treatment?
The firm maintains a 'Find a GammaTile Center' locator on its website mapping clinical sites across the United States. The treatment requires a neurosurgeon and a radiation-oncology team that have integrated GammaTile into their surgical workflow; patients identify a participating center through the locator and then confirm candidacy with the care team.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: